• FDA Approves Dupixent® for Chronic Rhinosinusitis with Nasal Polyposis americanpharmaceuticalreview
    June 27, 2019
    The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition ...
PharmaSources Customer Service